The key discoveries include ER+ BC: 13 targets, with RPS4X, RPL34, and VMP1 being more effective than ESR1; HER2+ BC: 44 targets, with some stronger than ERBB2, with enriched processes in mRNA decay and protein targeting; and TNBC: 29 targets, which are enriched in processes like protein targeting and mRNA processing. This evidence concerns the gene ERBB2 and breast cancer.